Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma (TTV ccRCC)

  • STATUS
    Recruiting
  • End date
    Jan 29, 2027
  • participants needed
    20
  • sponsor
    Regina Elena Cancer Institute
Send
Updated on 13 June 2025
See if I qualify

Summary

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

Description

The study involves the prospective recruitment of patients with metastatic clear cell renal cell carcinoma who begin a first line of treatment with immunotherapy at the UOC of Medical Oncology 1 of the Regina Elena Cancer Institute in Rome. Participants will undergo the following extra-clinical procedures and provided for by the protocol:

  • Explanation, reading and signing of the informed consent;
  • Performing a blood sample (approximately 7 ml);
  • Collection of fecal material at different timepoints. It should be noted that the procedures necessary for conducting the study will not affect the diagnostic and therapeutic process of the patients and will only have research purposes.

The biological material collected, appropriately labeled, processed at the reference laboratories, where it will be used to perform the planned analyses. Blood and/or stool samples will be collected at different timepoints:

  • Time zero (T0): before the start of therapy (blood and stool)
  • C2 (T1): before the start of cycle 2 (blood)
  • C4 (T2): after cycle 4, i.e. coinciding with the first radiological reassessment (blood and stool)
  • 22W or 19W (T3): after 12 weeks from C4 i.e. coinciding with the radiological reassessments (blood and stool), i.e. at the last timepoint of this study.

Additional blood sampling will be performed in the case of immune-related toxicity (≥ G2 according to CTCAE) requiring steroid administration.

An additional sampling, as assessed by the investigating physician, will be collected at the time of disease progression (PD) (T4).

For each patient included in the study, the following data will be collected (obtained from the clinical documentation from the analyses conducted): personal/socio-demographic data (year of birth, sex, gender), complete histology and date of first diagnosis, surgical treatments, clinical data (e.g., laboratory tests), clinical data relating to the treatment (start and end date of each therapy with number of cycles administered, response to treatment, date of disease progression), date and location of each disease progression, patient status, date of last available follow-up, date of any death, data obtained from the analyses carried out within the present project.

Details
Condition Renal Cell Carcinoma
Age 18years or above
Clinical Study IdentifierNCT07018037
SponsorRegina Elena Cancer Institute
Last Modified on13 June 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients over 18 years of age
Histological diagnosis of clear cell renal cell carcinoma
Evidence of advanced or metastatic disease
Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI)
Patients able to comply with the study procedures
Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started

Exclusion Criteria

Previous neoplasms
Previous antineoplastic treatments
Previous steroid treatments
Active viral infections (e.g., HCV, HIV, etc.)
Lack of autonomy in adhering to study procedures
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.